Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Historical Holders from Q2 2019 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
QNCX on Nasdaq
Shares outstanding
56,260,480
Price per share
$1.63
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
11,792,663
Holdings value
$19,221,893
% of all portfolios
0%
Share change
+4,213,876
Value change
+$6,863,060
Average buys %
+0%
Average sells %
-0%
Number of holders
45
Price from insider filings
$3.47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 10% 0% $9,156,792 +$1,392,249 5,620,422 +18% Nantahala Capital Management, LLC 30 Sep 2025
Sofinnova Partners SAS 2.7% -54% $1,185,734 -$1,188,000 1,197,711 -50% Sofinnova Capital VIII 31 Mar 2025
As of 30 Sep 2025, Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) has 45 institutional shareholders filing 13F forms. They hold 11,792,663 shares of 56,260,480 outstanding shares (21%) .

Top 25 institutional shareholders own 21% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Nantahala Capital Management, LLC 5.5% 3,073,729 +22% 0.31% $5,010,178
VANGUARD GROUP INC 3.1% 1,763,387 +21% 0% $2,874,320
MILLENNIUM MANAGEMENT LLC 2.5% 1,386,776 +1153% 0% $2,260,445
IEQ CAPITAL, LLC 1.7% 981,264 +123% 0% $1,599,460
ADAR1 Capital Management, LLC 1.4% 775,034 +442% 0.13% $1,263,305
Almitas Capital LLC 0.88% 494,778 0.18% $806,488
RENAISSANCE TECHNOLOGIES LLC 0.83% 468,598 +23% 0% $763,815
GEODE CAPITAL MANAGEMENT, LLC 0.78% 437,285 +10% 0% $712,910
BlackRock, Inc. 0.61% 345,461 +2.9% 0% $563,101
HighTower Advisors, LLC 0.55% 308,500 0% 0% $502,855
Union Square Park Capital Management, LLC 0.4% 224,746 +86% 0.25% $366,336
MARSHALL WACE, LLP 0.37% 210,045 0% $342,372
STATE STREET CORP 0.35% 198,111 +59% 0% $322,921
Alphabet Inc. 0.34% 189,122 0% 0.01% $308,269
Shay Capital LLC 0.24% 136,955 -8.7% 0.04% $223,237
Mariner, LLC 0.22% 122,461 0% 0% $199,611
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.17% 95,122 -26% 0% $155,049
SCHARF INVESTMENTS, LLC 0.16% 91,061 0% 0% $148,429
SIMPLEX TRADING, LLC 0.16% 88,519 0% $144,000
GSA CAPITAL PARTNERS LLP 0.16% 87,235 +158% 0.01% $142,000
NORTHERN TRUST CORP 0.12% 64,706 -16% 0% $105,471
CITADEL ADVISORS LLC 0.1% 56,914 -39% 0% $92,770
JANE STREET GROUP, LLC 0.06% 35,160 0% $57,311
Operose Advisors LLC 0.06% 31,568 0.01% $51,455
GROUP ONE TRADING LLC 0.05% 30,830 0% $50,253

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 11,792,663 $19,221,893 +$6,863,060 $1.63 45
2025 Q2 7,578,787 $12,505,248 +$3,952,656 $1.65 40
2025 Q1 5,230,260 $6,956,589 +$1,241,119 $1.33 35
2024 Q4 5,108,991 $9,553,550 +$495,078 $1.87 34
2024 Q3 5,193,769 $4,039,786 -$775,970 $0.7762 32
2024 Q2 6,247,425 $4,679,876 -$811,761 $0.7500 41
2024 Q1 7,272,011 $7,707,118 -$189,424 $1.06 44
2023 Q4 7,451,323 $7,825,763 -$54,129 $1.05 41
2023 Q3 7,501,451 $8,401,710 -$2,281,471 $1.12 40
2023 Q2 8,974,632 $13,507,225 +$1,945,492 $1.50 38
2023 Q1 7,677,996 $11,976,762 +$3,808,602 $1.56 41
2022 Q4 5,400,142 $3,438,849 -$3,310,463 $0.6374 46
2022 Q3 9,314,202 $12,384,077 -$3,927,969 $1.33 51
2022 Q2 11,700,511 $25,971,549 -$20,267,021 $2.22 60
2022 Q1 14,236,792 $88,111,251 -$45,899,789 $6.19 83
2021 Q4 19,237,596 $242,781,654 -$219,571,461 $12.62 95
2021 Q3 19,191,414 $1,759,087,977 +$80,924,604 $91.66 130
2021 Q2 18,545,330 $982,908,976 -$6,104,699 $53.00 104
2021 Q1 18,693,040 $673,491,454 +$37,011,077 $36.03 90
2020 Q4 17,656,872 $490,520,403 +$26,833,435 $27.78 84
2020 Q3 16,543,535 $826,995,550 +$55,308,755 $50.00 85
2020 Q2 15,442,796 $714,739,484 +$184,954,170 $46.30 82
2020 Q1 11,450,501 $522,757,976 +$39,593,805 $45.61 65
2019 Q4 10,588,023 $594,414,680 +$91,850,250 $56.14 51
2019 Q3 5,847,617 $144,973,494 +$81,320,822 $24.93 41
2019 Q2 2,421,805 $102,945,360 +$102,944,765 $42.51 37